GlassScriptPhysician profile
William Christopher Taylor
NPI 1700094174
$1,191.36
in general payments reported to CMS, 2019-2025
20 companies · $213 in 2025
The $213 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $14.20 · 2021: $144 · 2022: $122 · 2023: $46.43 · 2024: $191 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $311.54 | 2019-2025 | Tecvayli, Darzalex, Erleada |
| Pfizer INC. | $169.98 | 2019-2025 | |
| Seagen INC. | $98.95 | 2021 | |
| Celgene Corporation | $98.72 | 2023-2025 | Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $76.36 | 2019-2025 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $75.75 | 2019-2025 | Opdivo, Krazati |
| Amgen INC. | $57.67 | 2019 | |
| Abbvie INC. | $39.79 | 2021-2025 | |
| Genzyme Corporation | $36.63 | 2019 | |
| Exelixis INC. | $31.25 | 2019-2024 | Cabometyx |
| Gilead Sciences, INC. | $28.15 | 2019-2021 | |
| Genentech USA, INC. | $27.72 | 2019 | |
| Incyte Corporation | $23.94 | 2019-2021 | |
| Blue Earth Diagnostics | $19.45 | 2024 | |
| Boston Scientific Corporation | $19.38 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $18.11 | 2025 | Mektovi, Orgovyx, Braftovi |
| Pharmaessentia USA Corporation | $17.97 | 2024 | Besremi |
| Astrazeneca Pharmaceuticals LP | $15.77 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $13.51 | 2025 | Sancuso |
| Janssen Pharmaceuticals, INC | $10.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.